Our History

Our History of Firsts

Since our inception, every milestone has pushed us to the next, enabling us to transform the future of eye care.

1998

Glaukos is founded

2001

The first human implant of micro-bypass glaucoma stent is performed

2008

Glaukos receives Category III CPT code to describe insertion of a flow device into the trabecular meshwork of the eye

2013

Glaukos secures 100% Medicare coverage for the iStent® procedure

2015

Glaukos completes initial public offering

2017

Glaukos expands into 17 countries with direct sales operations

2019

Glaukos acquires Avedro, establishing the cornerstone of a new corneal health franchise

Glaukos acquires DOSE Medical, establishing a new R&D retinal program

Glaukos enters licensing agreement with Intratus for a non-invasive, cream-based drug delivery platform

1999

The first trabecular micro-bypass glaucoma stent is developed

2005

Landmark trial evaluating iStent® in conjunction with cataract surgery begins

2012

iStent® is approved by the FDA in combination with cataract surgery

Glaukos establishes a direct sales organization in the United States for iStent®

2014

Glaukos launches iStent inject® in Germany

Glaukos establishes a direct sales organization in Germany

2016

iStent® is approved in Japan

iStent® launches in Australia and Canada

2018

iStent inject® is approved by the FDA in combination with cataract surgery; US commercial launch

Glaukos enters pharmaceutical development agreement with D. Western, a preeminent research organization

2020

Glaukos exceeds 700,000 iStent® devices implanted

iStent inject® W is launched

The iLink corneal cross-linking procedure is introduced to the Glaukos family

Glaukos completes convertible debt financing

Glaukos issues inaugural sustainability report

1998

Glaukos is founded

1999

The first trabecular micro-bypass glaucoma stent is developed

2001

The first human implant of micro-bypass glaucoma stent is performed

2005

Landmark trial evaluating iStent® in conjunction with cataract surgery begins

2008

Glaukos receives Category III CPT code to describe insertion of a flow device into the trabecular meshwork of the eye

2012

iStent® is approved by the FDA in combination with cataract surgery

Glaukos establishes a direct sales organization in the United States for iStent®

2013

Glaukos secures 100% Medicare coverage for the iStent® procedure

2014

Glaukos launches iStent inject® in Germany

Glaukos establishes a direct sales organization in Germany

2015

Glaukos completes initial public offering

2016

iStent® is approved in Japan

iStent® launches in Australia and Canada

2017

Glaukos expands into 17 countries with direct sales operations

2018

iStent inject® is approved by the FDA in combination with cataract surgery; US commercial launch

Glaukos enters pharmaceutical development agreement with D. Western, a preeminent research organization

2019

Glaukos acquires Avedro, establishing the cornerstone of a new corneal health franchise

Glaukos acquires DOSE Medical, establishing a new R&D retinal program

Glaukos enters licensing agreement with Intratus for a non-invasive, cream-based drug delivery platform

2020

Glaukos exceeds 700,000 iStent® devices implanted

iStent inject® W is launched

The iLink corneal cross-linking procedure is introduced to the Glaukos family

Glaukos completes convertible debt financing

Glaukos issues inaugural sustainability report

Looking Ahead

Glaukos is actively developing microsurgical devices, pharmaceuticals, and biosensors for the treatment of chronic eye disease. Stay tuned!

Empowering ophthalmic growth worldwide

With direct sales operations in 17 countries, we employ more than 250 commercial sales personnel worldwide. And we serve additional international markets through relationships with valued distributors. In all, our technologies are currently approved for use in more than 30 countries, and we continue to pursue regulatory approvals in more regions.